{"url":"https://lda.senate.gov/api/v1/filings/8b9c8836-59ee-4947-beed-e2f8c1cdfddd/","filing_uuid":"8b9c8836-59ee-4947-beed-e2f8c1cdfddd","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2022,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/8b9c8836-59ee-4947-beed-e2f8c1cdfddd/print/","filing_document_content_type":"text/html","income":null,"expenses":"130000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Steve Giuli, Vice President of Government Affairs & Trade Relations","dt_posted":"2022-07-20T15:23:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2400 N. COMMERCE PARKWAY","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WESTON","registrant_state":"FL","registrant_zip":"33326","registrant":{"id":310973,"url":"https://lda.senate.gov/api/v1/registrants/310973/","house_registrant_id":38623,"name":"APOTEX CORP.","description":"Generic pharmaceutical manufacturer","address_1":"2400 N. COMMERCE PARKWAY","address_2":null,"address_3":null,"address_4":null,"city":"WESTON","state":"FL","state_display":"Florida","zip":"33326","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE GIULI","contact_telephone":"+1 954-384-8007","dt_updated":"2026-01-30T15:29:14.471073-05:00"},"client":{"id":183737,"url":"https://lda.senate.gov/api/v1/clients/183737/","client_id":12,"name":"APOTEX CORP.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"FL","state_display":"Florida","country":"US","country_display":"United States of America","ppb_state":"FL","ppb_state_display":"Florida","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2006-07-20"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 7667, the Food and Drug Amendments of 2022, Title III, Fees Relating to Generic Drugs, provisions relating to the reauthorization of the Generic Drug User Fee Act; S 4348, Food and Drug Safety and Landmark Advancement Act, Title III, Fees Relating to Generic Drugs, provisions relating to the reauthorization of the Generic Drug User Fee Act; Senator Tina Smith Amendment #1 to S 4348, provisions relating to amending the Hatch-Waxman 180 exclusivity structure to prevent market blockages; HR 2853, the BLOCKING Act, provisions relating to amending the Hatch-Waxman Act 180-day exclusivity structure; and S2910, Expanding Access to Low Cost Generics Act, provisions relating to amending the Hatch-Waxman Act's 180-day exclusivity structure.","foreign_entity_issues":"Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.","lobbyists":[{"lobbyist":{"id":41476,"prefix":null,"prefix_display":null,"first_name":"STEVEN","nickname":null,"middle_name":null,"last_name":"GIULI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}